RESEARCH ARTICLE |
|
Year : 2011 | Volume
: 43
| Issue : 6 | Page : 638-643 |
Racemic salbutamol and levosalbutamol in mild persistent asthma: A comparative study of efficacy and safety
Rituparna Maiti1, Chenimilla Nagender Prasad2, Jyothirmai Jaida1, Sruthi Mukkisa1, Narendar Koyagura1, Anuradha Palani1
1 Department of Pharmacology, Prathima Institute of Medical Sciences, Nagunur Road, Karimnagar, Andhra Pradesh, India 2 Department of Pulmonology, Prathima Institute of Medical Sciences, Nagunur Road, Karimnagar, Andhra Pradesh, India
Correspondence Address:
Rituparna Maiti Department of Pharmacology, Prathima Institute of Medical Sciences, Nagunur Road, Karimnagar, Andhra Pradesh India
 Source of Support: Institutional research fund, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.89817
Aim : The effect of monotherapy with racemic salbutamol and levosalbutamol on symptoms, quality of life, and pulmonary function has been assessed and compared in mild persistent asthma.
Materials and Methods : A randomized, open, parallel clinical study was conducted on 60 patients of mild persistent asthma. After baseline assessments, salbutamol was prescribed to 30 patients and levosalbutamol to another 30 for 4 weeks. The efficacy variables were change in asthma symptom scoring, pulmonary function test, and Mini Asthma Quality of Life Questionnaire (MiniAQLQ) scoring. At follow-up, the patients were re-evaluated and analyzed by statistical tools.
Results : Shortness of breath (P<0.001), chest tightness (P=0.033), wheeze (P=0.01), cough (P=0.024), and overall asthma symptom score (P<0.001) were significantly decreased in the levosalbutamol group in comparison to the salbutamol group. Results of MiniAQLQ revealed that improvement in symptoms (P=0.018), activity limitations (P=0.03), environmental stimuli (P=0.013)-related scoring and overall MiniAQLQ scoring (P<0.001) was statistically significant in the levosalbutamol group. Percentage reversibility of forced expiratory volume at one second (P=0.034), forced vital capacity (P=0.029), peak expiratory flow rate (P=0.0003) was found to be superior in the levosalbutamol group.
Conclusion : Levosalbutamol was found to be superior compared to recemic salbutamol in mild persistent asthma.
[FULL TEXT] [PDF]*
|